Amgen (AMGN) stock
Last close $438.82 on 2026-11-19 (-1.14%) · Sector: Healthcare
Amgen is a large American biopharmaceutical company based in Thousand Oaks, California, that develops and sells medicines made from biological sources, such as antibodies and other proteins. It earns most of its money by selling these prescription treatments to patients, hospitals, and healthcare providers around the world.
Amgen's sales are still growing, with trailing 12-month revenue of about $38.9 billion and growth of 8.1%. Over the past year the stock returned 30.6%, well ahead of the S&P 500's 9.7%, and it trades about 2.2% above its 50-day average and 14.6% above its 200-day average. Its balance sheet carries a lot of debt, and recent sales by company executives are listed, which beginners may want to weigh. After its last four earnings reports, the stock rose the next day three times and fell once.
Key numbers
- Market cap: $239.6B
- Revenue (last 12 months): $38.91B
- Revenue growth: +8.1%
- Gross margin: 70.8%
- Operating margin: 32.4%
- P/E: 25.5
- P/S: 6.2
- Debt to equity: 3.60
- Current ratio: 1.48
Quality score
Overall 30/100 · growth 36 · profitability 59 · financial health 0 · value 24
Performance and risk
1-year return +30.6% vs S&P 500 +9.7% · volatility 28.9% (S&P 500 13.8%) · largest drop -16.6% · beta 0.51
Stock move the day after earnings
- 2026-02-03: +8.2%
- 2026-04-30: -4.7%
- 2026-08-04: +4.6%
- 2026-11-03: +3.7%
Congress trades (90 days)
2 buys, 4 sells
Insider trades (12 months)
Bought $0.0M · sold $26.7M
AMGN stock research · AMGN options calculator · Stocks to buy, hold or sell today
StrikeWright provides AI signals only, not financial advice.